Brigham And Women's Hospital
Boston, Massachusetts, 02120, United States
NCT Number: NCT04772248
There are two main aims of this study.
First aim is to compare the risk of cardiovascular events (including myocardial infarction or stroke), between patients treated with tofacitinib and patients treated with TNF inhibitors (TNFi) for rheumatoid arthritis (RA) among, 1) "real world evidence (RWE)" cohorts including routine care patient population from the US and, 2) "Randomized controlled trial (RCT) DUPLICATE" cohorts including routine care patient population who meet inclusion and exclusion criteria of the Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis ("ORAL Surveillance", NCT02092467) clinical trial.
Second aim is to examine the risk of myocardial infarction, stroke, heart failure hospitalization, coronary revascularization, and all-cause mortality as separate endpoints when comparing tofacitinib with TNFi in patients with RA among, 1) "real world evidence (RWE)" cohort including routine care patient population from the US and, 2) "Randomized controlled trial (RCT) DUPLICATE" cohort including routine care patient population who meet inclusion and exclusion criteria of the Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis ("ORAL Surveillance", NCT02092467) clinical trial.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Boston, Massachusetts, 02120, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Criteria:
Please see https://www.bwhprime.org/resources.html for full code and algorithm definitions.
Eligible cohort entry dates:
Cohort entry date:
Inclusion and Exclusion Criteria Common to RWE and RCT-duplicate Cohorts:
Exclusion criteria
specific to RWE cohorts:
Inclusion criteria
specific to RCT-duplicate cohorts:
Exclusion criteria
specific to RCT-duplicate cohorts:
First eligible prescription for treating rheumatoid arthritis (RA)
First eligible prescription for treating rheumatoid arthritis (RA)
Other names: infliximab, adalimumab, certolizumab pegol, etanercept, golimumab
Time frame: Through study time period (2012-2020)
Myocardial infarction OR Stroke
Time frame: Through study time period (2012-2020)
Time frame: Through study time period (2012-2020)
Time frame: Through study time period (2012-2020)
Time frame: Through study time period (2012-2020)
Time frame: Through study time period (2012-2020)
Brigham and Women's Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01521923
Arthritis, Arthritis, Rheumatoid
Birmingham, Alabama, United States
View Trial DetailsNCT01519791
Arthritis, Arthritis, Rheumatoid
Birmingham, Alabama, United States
View Trial DetailsNCT05533372
Arthritis, Arthritis, Rheumatoid
Lenexa, Kansas, United States
View Trial DetailsNCT07772687
Arthritis, Arthritis, Psoriatic
Bonn, North Rhine-Westphalia, Germany
View Trial Details